# Genelux Corporation Common Stock (GNLX)

> Genelux Corporation Common Stock (GNLX) trades at $1.96 (+7.69%) as of 1:43:04 PM EST on Nov 6, 2026, -21.60% over the past month. Market cap is $82.35M, with 15.7 days to cover in short interest.

Canonical: https://massive.com/quote/gnlx
Data as of: 2026-11-06T18:43:04.092Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$1.96** +0.14 (+7.69%)
As of 1:43:04 PM EST on Nov 6, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Genelux Corporation Common Stock (GNLX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +7.69% |
| 1W | -5.77% |
| 1M | -21.60% |
| YTD | -55.05% |
| 1Y | -63.84% |
| 52-wk range | $1.77 – $6.26 |

From daily closes through Nov 6, 2026.

## Key statistics

Today's trading snapshot for GNLX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $1.81 – $1.99 |
| Open | $1.83 |
| Prev close | $1.82 |
| Volume | 185.89K |
| Market cap | $82.35M |
| Shares out | 45.25M |

## Valuation and profitability ratios

Valuation and profitability ratios for Genelux Corporation Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 10293.31 |
| P/B | 5.11 |
| P/FCF | — |
| ROE | -220.9% |
| ROA | -135.8% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 5, 2026

## Insider trading

[Genelux Corporation Common Stock (GNLX) insider trading](https://massive.com/quote/gnlx/insider-trading.md): open-market Form 4 buys and sells by Genelux Corporation Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Genelux Corporation Common Stock has disclosed to the SEC on Form 8-K.

- Mar 19, 2026 · Underwriting agreement
  “On March 19, 2026, Genelux Corporation (the "Company") entered into a Sales Agreement (the "Sales Agreement") with TD Securities (USA) LLC ("TD Cowen"), pursuant to which the Company may, from time to time, offer and sell shares of the Company's common stock, par value $0.001 per share (the "Placement Shares"), having an aggregate offering price of up to $100,000,000, through TD Cowen, acting as the Company's sales agent and/or principal.”
- Feb 2, 2026 · Investor presentation
  “On February 2, 2026, Genelux Corporation (the "Company") updated its corporate presentation (the "Corporate Presentation") with certain business and strategic updates. Information from the Corporate Presentation may be used by the management of the Company in future meetings regarding the Company and will also be available in the "Investors" section of the Company's website at investors.genelux.com.”
- Jan 8, 2026 · Underwriting agreement
  “The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended (the "Securities Act"), other obligations of the parties and termination provisions.”
- Jan 5, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On January 5, 2026, Genelux reported interim results from two ongoing trials evaluating systemic (intravenous) administration of Olvi-Vec in patients with progressive small cell lung cancer and progressive non-small cell lung cancer, respectively, after failure of prior platinum-based regimens. As of the data review cutoff date of December 23, 2025, systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved the following preliminary results: 9 evaluable patients, Overall response rate (ORR) of 33% (3/9 patients), including three partial responses (PRs), and Disease control rate (DCR) of 67% (6/9 patients).”
- Jan 2, 2026 · Executive officer appointment
  “On January 2, 2026, the Company announced the appointment of Jason Litten, M.D. as the Company's Chief Medical Officer, effective as of January 2, 2026. Dr. Litten, 52, most recently served as the Chief Medical Officer of Chimeric Therapeutics, Ltd. since July 2022. Dr. Litten is an expert in clinical oncology with experience developing numerous therapeutics modalities.”

## GNLX short interest

How heavily GNLX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 15.7 |
| Short interest | 4.64M |
| Avg volume | 295.51K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## GNLX news

The latest news and headlines about Genelux Corporation Common Stock (GNLX).

- [Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners](https://www.globenewswire.com/news-release/2026/01/12/3217338/0/en/Genelux-Corporation-Announces-Upcoming-Virtual-Fireside-Chat-Hosted-by-Titan-Partners.html) · GlobeNewswire Inc. · Jan 12, 2026 · neutral sentiment
- [Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer](https://www.globenewswire.com/news-release/2026/01/02/3212119/0/en/Genelux-Corporation-Announces-Appointment-of-Jason-Litten-M-D-as-Chief-Medical-Officer.html) · GlobeNewswire Inc. · Jan 2, 2026 · positive sentiment
- [Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference](https://www.globenewswire.com/news-release/2024/09/03/2940065/0/en/Genelux-Corporation-to-Present-at-the-H-C-Wainwright-Global-Investment-Conference.html) · GlobeNewswire Inc. · Sep 3, 2024 · positive sentiment
- [Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024](https://www.globenewswire.com/news-release/2024/07/30/2920840/0/en/Genelux-Corporation-to-Participate-in-Fireside-Chat-at-BTIG-s-Virtual-Biotechnology-Conference-2024.html) · GlobeNewswire Inc. · Jul 30, 2024 · positive sentiment
- [Unveiling 4 Analyst Insights On Genelux](https://www.benzinga.com/insights/analyst-ratings/24/05/39115151/unveiling-4-analyst-insights-on-genelux) · Benzinga · May 31, 2024

## About Genelux Corporation Common Stock

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 26 |
| Listed | Jan 26, 2023 |

[Company website](https://www.genelux.com)

## FAQ

### What is the Genelux Corporation Common Stock (GNLX) stock price today?

Genelux Corporation Common Stock (GNLX) is trading at $1.96 (+7.69% on the day) as of 1:43:04 PM EST on Nov 6, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Genelux Corporation Common Stock?

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens.

### What is the short interest in GNLX?

As of Oct 15, 2026, GNLX has 4.64M shares short and 15.7 days to cover.

### What exchange is GNLX listed on?

Genelux Corporation Common Stock (GNLX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time GNLX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=GNLX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Genelux Corporation Common Stock (GNLX) insider trading](https://massive.com/quote/gnlx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms